Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 May;133(5):1383-9, 1389.e1-6.
doi: 10.1016/j.jaci.2013.10.060. Epub 2014 Jan 17.

Component resolution reveals additional major allergens in patients with honeybee venom allergy

Julian Köhler  1 , Simon Blank  2 , Sabine Müller  1 , Frank Bantleon  2 , Marcel Frick  1 , Johannes Huss-Marp  3 , Jonas Lidholm  4 , Edzard Spillner  5 , Thilo Jakob  6
Affiliations
Free article
Clinical Trial

Component resolution reveals additional major allergens in patients with honeybee venom allergy

Julian Köhler et al. J Allergy Clin Immunol. 2014 May.
Free article

Abstract

Background: Detection of IgE to recombinant Hymenoptera venom allergens has been suggested to improve the diagnostic precision in Hymenoptera venom allergy. However, the frequency of sensitization to the only available recombinant honeybee venom (HBV) allergen, rApi m 1, in patients with HBV allergy is limited, suggesting that additional HBV allergens might be of relevance.

Objective: We performed an analysis of sensitization profiles of patients with HBV allergy to a panel of HBV allergens.

Methods: Diagnosis of HBV allergy (n = 144) was based on history, skin test results, and allergen-specific IgE levels to HBV. IgE reactivity to 6 HBV allergens devoid of cross-reactive carbohydrate determinants (CCD) was analyzed by ImmunoCAP.

Results: IgE reactivity to rApi m 1, rApi m 2, rApi m 3, nApi m 4, rApi m 5, and rApi m 10 was detected in 72.2%, 47.9%, 50.0%, 22.9%, 58.3%, and 61.8% of the patients with HBV allergy, respectively. Positive results to at least 1 HBV allergen were detected in 94.4%. IgE reactivity to Api m 3, Api m 10, or both was detected in 68.0% and represented the only HBV allergen-specific IgE in 5% of the patients. Limited inhibition of IgE binding by therapeutic HBV and limited induction of Api m 3- and Api m 10-specific IgG4 in patients obtaining immunotherapy supports recent reports on the underrepresentation of these allergens in therapeutic HBV preparations.

Conclusion: Analysis of a panel of CCD-free HBV allergens improved diagnostic sensitivity compared with use of rApi m 1 alone, identified additional major allergens, and revealed sensitizations to allergens that have been reported to be absent or underrepresented in therapeutic HBV preparations.

Keywords: Apis mellifera; Hymenoptera venom; Vespula vulgaris; cross-reactive carbohydrate determinant; honeybee venom allergy; insect venom allergy; recombinant allergen.

PubMed Disclaimer